Keeping expanded access programs in context-Reference-Cited by-同舟云学术

Keeping expanded access programs in context

Published:2023-03-09 Issue:5 Volume:67 Page:337-338
ISSN:0148-639X
Container-title:Muscle & Nerve
language:en
Short-container-title:Muscle and Nerve

Author:

Caress James B.¹^ORCID

Affiliation:

1. Department of Neurology Wake Forest School of Medicine Winston‐Salem North Carolina USA

Abstract

See article on pages 354–362 in this issue.

Publisher

Wiley

Subject

Physiology (medical),Cellular and Molecular Neuroscience,Neurology (clinical),Physiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mus.27802

Reference8 articles.

1. Recommendations to Facilitate Expanded Access to Investigational Therapies for Seriously Ill Patients

2. Providing Patients with Critical or Life-Threatening Illnesses Access to Experimental Drug Therapy: A Guide to Clinical Trials and the US FDA Expanded Access Program

3. 1 USC 321 331 351 352 353 355 360bbb 371; 42 USC 262. Subpart I—expanded access to investigational drugs for treatment use. Updated November 29 2022.https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=312&showFR=1&subpartNode=21:5.0.1.1.3.9. Accessed December 27 2022.

4. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

5. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multicenter expanded access program for access to investigational products for amyotrophic lateral sclerosis;Muscle & Nerve;2024-06-06